Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agreed
Cheer!
Pete
Agreed
Go $GEQU
LOL.....been waiting for almost a year to get it
$AHIX will watch it my Friend
$AHIX Aluf Holdings, Inc. Updates its Shareholders on its Acquisition of Triad Biometrics, LLC and the Launch of its New Regulatory Compliance Software Subsidiary
HOLLYWOOD, FL / ACCESSWIRE / March 9, 2016 / Aluf Holdings, Inc. (AHIX) today updates its shareholders on the previously announced acquisition of Triad Biometrics, LLC. and the launch of its new Regulatory Compliance Software subsidiary. Teresa McWilliams, CEO of Aluf Holdings Inc. states, "We are pleased to be making such strides in bringing value to our shareholders with these acquisitions and felt the need to update our shareholders on its current milestones. We feel these acquisitions finally put us closer in the direction we need for up listing to a higher exchange."
Aluf Holdings is working towards completing the next phase of its acquisition of Triad Biometrics, LLC and has completed a satisfactory due diligence of Triad Biometrics which have simultaneously completed a satisfactory due diligence of Aluf Holdings.
Both companies completing the due diligence phase brings them closer towards the completion of the acquisition. Pursuant to the terms of the Purchase Agreement, the Company will pay Triad US$3,750,000 for the Assets.
Triad Biometrics, LLC. is a biometric software innovator formed in 2004, with software products including "undefeatable" FIPS 140-2 Suite B military grade encryption and various biometrics applications among other ground breaking features. The global encryption software market is expected to reach $2.16 billion by 2020, growing at a compounded annual growth rate of 14.27% from 2014 to 2020 (by Allied Market Research). BCC Research among many others is predicting the global biometrics market to grow at a rate of 22.7 compounded annual growth rate between 2015 and 2020. That will see the market grow from an estimated $14.9 billion last year to $41.5 billion by 2020.
Aluf Holdings Inc., is further pleased to update its shareholders on its acquisition of its new Regulatory Compliance Software and the launch of a new subsidiary for the Company focusing on assisting security firms, such as banks, law firms, clearing firms, and broker dealers that sell investment products to the public to comply with rules and regulations of the securities industry. It will also help reduce compliance/supervision costs while improving regulatory compliance. This cost effective software solution will also help management monitor account activities. "We are days away from executing the definitive purchase agreement for this copyrighted software acquisition, allowing the Company to once again bring value to its shareholders in a rapidly growing industry," said Teresa McWilliams, CEO Aluf Holdings, Inc. Firms will pay a one-time setup fee that covers establishing a master account, populating individual tables, mapping data files, testing data file exchange and providing system training.
About Triad Biometrics, LLC:
Triad Biometrics, LLC, developed TEAMS(R), a groundbreaking enterprise level fingerprint biometric identification and authentication product that is setting a new paradigm for security, interoperability, and accountability. TEAMS(R) represents the next-generation in securely accessing web based applications. By enabling the elimination of passwords and password fields, data security, end user experience, and productivity are significantly improved while authentication-related maintenance and operating costs are reduced. User frustration and risk associated with finding, remembering, and storing passwords is eliminated. Unlike other commercial biometric systems, TEAMS(R) is an autonomous authentication method with no reliance on directory or other password-based systems, and once implemented, cannot be hacked, cracked, or circumvented. TEAMS(R) utilizes military-grade FIPS-140 Suite B cryptography in concert with several unique patented and pending features which enable a never-before-obtained level of identity confidence, privacy protection, and data security over un-trusted networks, such as the public internet. Visit: www.triadbiometrics.com.
About Aluf Holdings:
Aluf Holdings, Inc. (AHIX) is a holding company headquartered in Hollywood, FL, engaged in acquiring, operating and managing subsidiary companies in the development and sale of proprietary software. Its strategy is to build a larger and more diverse enterprise software company through strategic acquisitions and managed growth within its business sectors as it acquires profitable businesses with strong growth potential and a solid business plan in the software and technology industries. For information, visit www.alufinc.com.
Safe Harbor Statement:
This release may contain "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and of Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief, or current expectations of Aluf Holdings, Inc. and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-looking statements include fluctuation of operating results, the ability to compete successfully in its market segment, and the ability to complete some or all of the before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events, or changes to future operating results.
Corporate Contact:
Aluf Holdings, Inc.
Teresa McWilliams, CEO
866-793-1110
Investor Relations Contact:
High Point Communication
858-381-4677
SOURCE: Aluf Holdings, Inc.
$AHIX Aluf Holdings, Inc. Updates its Shareholders on its Acquisition of Triad Biometrics, LLC and the Launch of its New Regulatory Compliance Software Subsidiary
HOLLYWOOD, FL / ACCESSWIRE / March 9, 2016 / Aluf Holdings, Inc. (AHIX) today updates its shareholders on the previously announced acquisition of Triad Biometrics, LLC. and the launch of its new Regulatory Compliance Software subsidiary. Teresa McWilliams, CEO of Aluf Holdings Inc. states, "We are pleased to be making such strides in bringing value to our shareholders with these acquisitions and felt the need to update our shareholders on its current milestones. We feel these acquisitions finally put us closer in the direction we need for up listing to a higher exchange."
Aluf Holdings is working towards completing the next phase of its acquisition of Triad Biometrics, LLC and has completed a satisfactory due diligence of Triad Biometrics which have simultaneously completed a satisfactory due diligence of Aluf Holdings.
Both companies completing the due diligence phase brings them closer towards the completion of the acquisition. Pursuant to the terms of the Purchase Agreement, the Company will pay Triad US$3,750,000 for the Assets.
Triad Biometrics, LLC. is a biometric software innovator formed in 2004, with software products including "undefeatable" FIPS 140-2 Suite B military grade encryption and various biometrics applications among other ground breaking features. The global encryption software market is expected to reach $2.16 billion by 2020, growing at a compounded annual growth rate of 14.27% from 2014 to 2020 (by Allied Market Research). BCC Research among many others is predicting the global biometrics market to grow at a rate of 22.7 compounded annual growth rate between 2015 and 2020. That will see the market grow from an estimated $14.9 billion last year to $41.5 billion by 2020.
Aluf Holdings Inc., is further pleased to update its shareholders on its acquisition of its new Regulatory Compliance Software and the launch of a new subsidiary for the Company focusing on assisting security firms, such as banks, law firms, clearing firms, and broker dealers that sell investment products to the public to comply with rules and regulations of the securities industry. It will also help reduce compliance/supervision costs while improving regulatory compliance. This cost effective software solution will also help management monitor account activities. "We are days away from executing the definitive purchase agreement for this copyrighted software acquisition, allowing the Company to once again bring value to its shareholders in a rapidly growing industry," said Teresa McWilliams, CEO Aluf Holdings, Inc. Firms will pay a one-time setup fee that covers establishing a master account, populating individual tables, mapping data files, testing data file exchange and providing system training.
About Triad Biometrics, LLC:
Triad Biometrics, LLC, developed TEAMS(R), a groundbreaking enterprise level fingerprint biometric identification and authentication product that is setting a new paradigm for security, interoperability, and accountability. TEAMS(R) represents the next-generation in securely accessing web based applications. By enabling the elimination of passwords and password fields, data security, end user experience, and productivity are significantly improved while authentication-related maintenance and operating costs are reduced. User frustration and risk associated with finding, remembering, and storing passwords is eliminated. Unlike other commercial biometric systems, TEAMS(R) is an autonomous authentication method with no reliance on directory or other password-based systems, and once implemented, cannot be hacked, cracked, or circumvented. TEAMS(R) utilizes military-grade FIPS-140 Suite B cryptography in concert with several unique patented and pending features which enable a never-before-obtained level of identity confidence, privacy protection, and data security over un-trusted networks, such as the public internet. Visit: www.triadbiometrics.com.
About Aluf Holdings:
Aluf Holdings, Inc. (AHIX) is a holding company headquartered in Hollywood, FL, engaged in acquiring, operating and managing subsidiary companies in the development and sale of proprietary software. Its strategy is to build a larger and more diverse enterprise software company through strategic acquisitions and managed growth within its business sectors as it acquires profitable businesses with strong growth potential and a solid business plan in the software and technology industries. For information, visit www.alufinc.com.
Safe Harbor Statement:
This release may contain "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and of Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief, or current expectations of Aluf Holdings, Inc. and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-looking statements include fluctuation of operating results, the ability to compete successfully in its market segment, and the ability to complete some or all of the before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events, or changes to future operating results.
Corporate Contact:
Aluf Holdings, Inc.
Teresa McWilliams, CEO
866-793-1110
Investor Relations Contact:
High Point Communication
858-381-4677
SOURCE: Aluf Holdings, Inc.
$DCAC all headline news about DCAC
https://finance.yahoo.com/q/h?s=DCAC+Headlines
$DCAC all headline news about DCAC
https://finance.yahoo.com/q/h?s=DCAC+Headlines
$LVGI ~ Limitless Venture Group Inc. due diligence report
$LVGI recent news/filings
https://finance.yahoo.com/q/h?s=LVGI+Headlines
$LVGI charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$LVGI company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/LVGI/company-info
Ticker: $LVGI
OTC Market Place: OTC Pink Current
CIK code: 0000874993
Company name: Limitless Venture Group Inc.
Company website: http://www.lvginc.com
Incorporated In: NV, USA
Business Description: Limitless Venture Group, Inc. (LVGI) known as THE BRAND BUILDERS is a development stage company dedicated to the production, distribution and marketing of unique, quality product lines. LVGI acts as a brand incubator bringing products from concept to reality then releasing them as stand alone companies.Limitless Venture Group, Inc. is a full service brand development company with an in house Bio-Chemical engineering and formulations department, in-house brand identity team, full graphics department as well as an experienced and highly motivated group of marketing professionals. Limitless Venture Group Inc. and its group of diversified wholly owned subsidiaries have four product lines ready to go to market. Through our Limitless Body Inc. sub we have our Limitless Body and our Limitless Health product lines fully developed, tested and ready for full production. Limitless Venture Group, Inc. also controls as a 100% wholly owned subsidiary named Limitless Brands Inc. Limitless Brands Inc. serves as our alcoholic brand division. SLAM Infusination is our line of RTD (ready to drink) alcoholic shots aimed at the virtually untapped grab and go counter item space of the massive alcohol industry. SLAM has it owns formulation, graphics and marketing department. Through Limitless Health? and our URL www.hempcorehealth.com, we market our HempCore Health? line of products. The initial product lineup consists of five products: Healthy Heart - a cholesterol reduction formula; Relax - an anti-anxiety/stress relief formula; Brain Boost - a cognitive/brain function enhancement formula; Fibered UP - a fiber supplement and Joint Relief - a joint/arthritis relief formula.Less >>
$LVGI share structure
## source: otcmarkets.com
Market Value: $1,240,189 a/o Aug 28, 2015
Shares Outstanding: 2,480,378,000 a/o Jan 19, 2015
Float: 2,480,378,000 a/o Jan 19, 2015
Authorized Shares: 3,500,000,000 a/o Dec 04, 2014
Par Value: Not Available
$LVGI extra dd links
Company name: Limitless Venture Group Inc.
Company website: http://www.lvginc.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=LVGI+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=LVGI+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=LVGI+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/LVGI/news - http://finance.yahoo.com/q/h?s=LVGI+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/LVGI/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/LVGI/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=LVGI+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/LVGI
DTCC (dtcc.com): http://search2.dtcc.com/?q=Limitless+Venture+Group+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Limitless+Venture+Group+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Limitless+Venture+Group+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.lvginc.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.lvginc.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.lvginc.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/LVGI
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000874993&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/LVGI/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/LVGI/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=LVGI&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=LVGI
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/LVGI/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=LVGI+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=LVGI+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=LVGI
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=LVGI
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=LVGI+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/LVGI/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=LVGI+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/LVGI.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=LVGI
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/LVGI/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/LVGI
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/LVGI
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/LVGI:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=LVGI
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=LVGI
$LVGI ~ Limitless Venture Group Inc. due diligence report
$LVGI recent news/filings
https://finance.yahoo.com/q/h?s=LVGI+Headlines
$LVGI charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$LVGI company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/LVGI/company-info
Ticker: $LVGI
OTC Market Place: OTC Pink Current
CIK code: 0000874993
Company name: Limitless Venture Group Inc.
Company website: http://www.lvginc.com
Incorporated In: NV, USA
Business Description: Limitless Venture Group, Inc. (LVGI) known as THE BRAND BUILDERS is a development stage company dedicated to the production, distribution and marketing of unique, quality product lines. LVGI acts as a brand incubator bringing products from concept to reality then releasing them as stand alone companies.Limitless Venture Group, Inc. is a full service brand development company with an in house Bio-Chemical engineering and formulations department, in-house brand identity team, full graphics department as well as an experienced and highly motivated group of marketing professionals. Limitless Venture Group Inc. and its group of diversified wholly owned subsidiaries have four product lines ready to go to market. Through our Limitless Body Inc. sub we have our Limitless Body and our Limitless Health product lines fully developed, tested and ready for full production. Limitless Venture Group, Inc. also controls as a 100% wholly owned subsidiary named Limitless Brands Inc. Limitless Brands Inc. serves as our alcoholic brand division. SLAM Infusination is our line of RTD (ready to drink) alcoholic shots aimed at the virtually untapped grab and go counter item space of the massive alcohol industry. SLAM has it owns formulation, graphics and marketing department. Through Limitless Health? and our URL www.hempcorehealth.com, we market our HempCore Health? line of products. The initial product lineup consists of five products: Healthy Heart - a cholesterol reduction formula; Relax - an anti-anxiety/stress relief formula; Brain Boost - a cognitive/brain function enhancement formula; Fibered UP - a fiber supplement and Joint Relief - a joint/arthritis relief formula.Less >>
$LVGI share structure
## source: otcmarkets.com
Market Value: $1,240,189 a/o Aug 28, 2015
Shares Outstanding: 2,480,378,000 a/o Jan 19, 2015
Float: 2,480,378,000 a/o Jan 19, 2015
Authorized Shares: 3,500,000,000 a/o Dec 04, 2014
Par Value: Not Available
$LVGI extra dd links
Company name: Limitless Venture Group Inc.
Company website: http://www.lvginc.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=LVGI+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=LVGI+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=LVGI+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/LVGI/news - http://finance.yahoo.com/q/h?s=LVGI+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/LVGI/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/LVGI/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=LVGI+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/LVGI
DTCC (dtcc.com): http://search2.dtcc.com/?q=Limitless+Venture+Group+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Limitless+Venture+Group+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Limitless+Venture+Group+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.lvginc.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.lvginc.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.lvginc.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/LVGI
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000874993&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/LVGI/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/LVGI/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=LVGI&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=LVGI
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/LVGI/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=LVGI+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=LVGI+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=LVGI
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=LVGI
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=LVGI+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/LVGI/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=LVGI+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/LVGI.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=LVGI
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/LVGI/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/LVGI/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/LVGI
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/LVGI
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/LVGI:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=LVGI
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=LVGI
$ISBG Signs 5-year Deal with MetLife Stadium
HOUSTON, Sept. 17, 2015 /PRNewswire/ -- International Spirit and Beverage Group (a Nevada Corporation) (ISBG) is pleased to announce that the company has signed a five-year contract with options for renewal after the fifth year with MetLife Stadium and the Quest Diagnostic Training Center in an all-cash transaction. MetLife Stadium will promote ISBG and its brands through various avenues in and around the stadium complex while the ISBG stable of brands will be available for sale at the bars and suites.
"This deal brings our Besado Tequila, Dziaq Liqueur and Cavoda Vodka brands front and center to the largest alcohol market in the nation," said Jeff Freiberger, ISBG's Chief Operating Officer. "We anticipate that this will create immediate, high demand for our products. The New York metropolitan market represents over 23 million people which is equal to over 7% of the U.S. population according to the US Census Bureau."
MetLife Stadium, home to the fourth and sixth most valuable professional football franchises (according to Forbes), is the perfect showcase for ISBG's premium brands of liquors.
"MetLife Stadium is a state of the art entertainment mecca for sports as well as concerts that always draws a capacity crowd," Freiberger continued. "ISBG will have pre- and post-game spots on the Jumbo-Tron, significant L-Wrap exposure on high definition TVs throughout the stadium, advertisements in game programs, spots on radio broadcasts, train station signage, external billboards and that is only just the beginning."
In addition to the benefits derived from the 80,000 people attending each football game, ISBG will have a presence at every concert held at MetLife Stadium.
"The ISBG signage and ISBG-sponsored bars will continue to operate beyond the end of the football season," Freiberger added. "Concert goers will be able to enjoy our brands at the stadium bars. ISBG benefits by reaching a significant new audience."
Related Quotes
ISBG
0.0005
-8.33%
International Spirit & Beverag …? Watchlist
0.0005-0.00(8.33%)
OTC MarketsFri, Mar 18, 2016 3:54 PM EDT
INTERNATIONAL SPIRIT & BEVERAGE GROUP, INC. Financials EDGAR Online Financials 2 mths ago
More
Freiberger notes that not only is this deal unique but he expects it to yield tremendous dividends to ISBG, even in year one of the contract. ISBG will also be a pillar for local charitable needs in a give back program to be announced
"ISBG is extremely proud and excited to have signed a deal of this magnitude in one of the premiere entertainment facilities in the nation," Freiberger concluded.
International Spirit and Beverage Group is an authorized importer, licensor, and marketer of alcoholic beverages. Our initial portfolio consists of Besado Tequila, Dziaq Liqueur, and Cavoda Vodka. The company website for ISBG is currently active. Check out our progress at www.isbg.global and visit us at @drinkisbg
This news release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. When used in this release, words such as "estimate," "expect," "anticipate," "projected," "planned," "forecasted" and similar expressions are intended to identify forward-looking statements, which are, by their very nature, no guarantees of ISBG's future operational or financial performance, and are subject to risks and uncertainties. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Due to the risks and uncertainties, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Notice Regarding Forward Looking Statements:
This news release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. When used in this release, words such as "estimate", "expect", "anticipate", "projected", "planned", "forecasted", and similar expressions are intended to identify forward-looking statements, which are, by their very nature, no guarantees of ISBG's future operational or financial performance, and are subject to risks and uncertainties. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Due to the risks and uncertainties, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
@drinkisbg
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/isbg-signs-5-year-deal-with-metlife-stadium-300144920.html
$ISBG Signs 5-year Deal with MetLife Stadium
HOUSTON, Sept. 17, 2015 /PRNewswire/ -- International Spirit and Beverage Group (a Nevada Corporation) (ISBG) is pleased to announce that the company has signed a five-year contract with options for renewal after the fifth year with MetLife Stadium and the Quest Diagnostic Training Center in an all-cash transaction. MetLife Stadium will promote ISBG and its brands through various avenues in and around the stadium complex while the ISBG stable of brands will be available for sale at the bars and suites.
"This deal brings our Besado Tequila, Dziaq Liqueur and Cavoda Vodka brands front and center to the largest alcohol market in the nation," said Jeff Freiberger, ISBG's Chief Operating Officer. "We anticipate that this will create immediate, high demand for our products. The New York metropolitan market represents over 23 million people which is equal to over 7% of the U.S. population according to the US Census Bureau."
MetLife Stadium, home to the fourth and sixth most valuable professional football franchises (according to Forbes), is the perfect showcase for ISBG's premium brands of liquors.
"MetLife Stadium is a state of the art entertainment mecca for sports as well as concerts that always draws a capacity crowd," Freiberger continued. "ISBG will have pre- and post-game spots on the Jumbo-Tron, significant L-Wrap exposure on high definition TVs throughout the stadium, advertisements in game programs, spots on radio broadcasts, train station signage, external billboards and that is only just the beginning."
In addition to the benefits derived from the 80,000 people attending each football game, ISBG will have a presence at every concert held at MetLife Stadium.
"The ISBG signage and ISBG-sponsored bars will continue to operate beyond the end of the football season," Freiberger added. "Concert goers will be able to enjoy our brands at the stadium bars. ISBG benefits by reaching a significant new audience."
Related Quotes
ISBG
0.0005
-8.33%
International Spirit & Beverag …? Watchlist
0.0005-0.00(8.33%)
OTC MarketsFri, Mar 18, 2016 3:54 PM EDT
INTERNATIONAL SPIRIT & BEVERAGE GROUP, INC. Financials EDGAR Online Financials 2 mths ago
More
Freiberger notes that not only is this deal unique but he expects it to yield tremendous dividends to ISBG, even in year one of the contract. ISBG will also be a pillar for local charitable needs in a give back program to be announced
"ISBG is extremely proud and excited to have signed a deal of this magnitude in one of the premiere entertainment facilities in the nation," Freiberger concluded.
International Spirit and Beverage Group is an authorized importer, licensor, and marketer of alcoholic beverages. Our initial portfolio consists of Besado Tequila, Dziaq Liqueur, and Cavoda Vodka. The company website for ISBG is currently active. Check out our progress at www.isbg.global and visit us at @drinkisbg
This news release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. When used in this release, words such as "estimate," "expect," "anticipate," "projected," "planned," "forecasted" and similar expressions are intended to identify forward-looking statements, which are, by their very nature, no guarantees of ISBG's future operational or financial performance, and are subject to risks and uncertainties. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Due to the risks and uncertainties, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Notice Regarding Forward Looking Statements:
This news release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. When used in this release, words such as "estimate", "expect", "anticipate", "projected", "planned", "forecasted", and similar expressions are intended to identify forward-looking statements, which are, by their very nature, no guarantees of ISBG's future operational or financial performance, and are subject to risks and uncertainties. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Due to the risks and uncertainties, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
@drinkisbg
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/isbg-signs-5-year-deal-with-metlife-stadium-300144920.html
$ISBG The New York Football Giants Team Up With ISBG
HOUSTON, Oct. 27, 2015 /PRNewswire/ -- International Spirit and Beverage Group, Inc. (ISBG) (ISBG) is pleased to announce the signing of a multi-year sponsorship deal with the New York Football Giants which will highlight Besado Tequila and Cavoda Vodka brands while also promoting a responsible drinking message. The partnership, which is effective immediately, will bring ISBG products to the forefront of the largest market in the nation.
To kick off this partnership, ISBG has proudly branded and opened up Club Cavoda in MetLife Stadium which combines a New York City high energy atmosphere with passionate football fans during each home game. In addition to Club Cavoda, ISBG will raise brand awareness with the Giants faithful through game-day branding at MetLife Stadium, radio commercials, and hospitality.
ISBG will also receive usage rights to the New York Giants trademarks in conjunction with the Cavoda Vodka and Besado Tequila brands in New York, New Jersey, and Connecticut. These trademarks will be utilized in on- and off- premise point of sale material, select advertising and store displays.
"We look forward to a long and successful relationship with the Giants and MetLife Stadium," stated Jeff Freiberger, ISBG's Chief Operating Officer. "The New York Giants have a lengthy and prosperous football heritage and we are proud to be partnered with this historic franchise."
"ISBG's passion for football, our fans, and the Giants brand was very evident to us, and we look forward to bringing their energy and love of the game to our fans," said Mike Stevens, Chief Marketing Officer New York Giants.
"By way of association with a sports franchise known the world over, we feel it will provide the exposure needed for ISBG brand recognition," stated Terry Williams, ISBG's Chief Executive Officer. "In addition, we anticipate it will build instant brand loyalty."
Related Quotes
ISBG
0.0005
-8.33%
International Spirit & Beverag …? Watchlist
0.0005-0.00(8.33%)
OTC MarketsFri, Mar 18, 2016 3:54 PM EDT
INTERNATIONAL SPIRIT & BEVERAGE GROUP, INC. Financials EDGAR Online Financials 2 mths ago
More
ISBG believes the diverse exposure across Giants platforms will further pave the way to an extremely bright near-term future. While ISBG management couldn't be more excited about its relationship with the New York Giants, this is just the first of many major sponsorship deals in the pipeline.
About New York Giants:
A cornerstone franchise of the National Football League, the New York Football Giants began play in 1925. With eight championships, including a victory over the New England Patriots in Super Bowl XLIV, their second in five seasons, the Giants are the only franchise in the NFL with a Super Bowl victory in each of the last four decades. Headquartered at the Quest Diagnostics Training Center in East Rutherford, N.J., the Giants entered their 91st season of play this fall. www.giants.com
About (ISBG) International Spirit and Beverage Group:
International Spirit and Beverage Group is an authorized importer, licensor, and marketer of alcoholic beverages. The ISBG initial portfolio consists of Besado Tequila, Dziaq Liqueur, and Cavoda Vodka. To learn more about ISBG, please visit www.isbg.global or @drinkisbg on Twitter.
About ISBG Mission:
Our mission at ISBG is to cultivate an atmosphere of excellence and spiritual values. We exist to create experiences where passion and purpose come together. We are certainly in the pursuit of becoming a leader in the industry, while at the same time using business to inspire.
We value our relationship with the community we serve, and the opportunity to encourage and mentor children across the globe.
We will continue to build the best products; while we help our customers celebrate life.
Notice Regarding Forward Looking Statements:
This news release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. When used in this release, words such as "estimate", "expect", "anticipate", "projected", "planned", "forecasted", and similar expressions are intended to identify forward-looking statements, which are, by their very nature, no guarantees of ISBG's future operational or financial performance, and are subject to risks and uncertainties. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Due to the risks and uncertainties, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-new-york-football-giants-team-up-with-isbg-300167069.html
$ISBG The New York Football Giants Team Up With ISBG
HOUSTON, Oct. 27, 2015 /PRNewswire/ -- International Spirit and Beverage Group, Inc. (ISBG) (ISBG) is pleased to announce the signing of a multi-year sponsorship deal with the New York Football Giants which will highlight Besado Tequila and Cavoda Vodka brands while also promoting a responsible drinking message. The partnership, which is effective immediately, will bring ISBG products to the forefront of the largest market in the nation.
To kick off this partnership, ISBG has proudly branded and opened up Club Cavoda in MetLife Stadium which combines a New York City high energy atmosphere with passionate football fans during each home game. In addition to Club Cavoda, ISBG will raise brand awareness with the Giants faithful through game-day branding at MetLife Stadium, radio commercials, and hospitality.
ISBG will also receive usage rights to the New York Giants trademarks in conjunction with the Cavoda Vodka and Besado Tequila brands in New York, New Jersey, and Connecticut. These trademarks will be utilized in on- and off- premise point of sale material, select advertising and store displays.
"We look forward to a long and successful relationship with the Giants and MetLife Stadium," stated Jeff Freiberger, ISBG's Chief Operating Officer. "The New York Giants have a lengthy and prosperous football heritage and we are proud to be partnered with this historic franchise."
"ISBG's passion for football, our fans, and the Giants brand was very evident to us, and we look forward to bringing their energy and love of the game to our fans," said Mike Stevens, Chief Marketing Officer New York Giants.
"By way of association with a sports franchise known the world over, we feel it will provide the exposure needed for ISBG brand recognition," stated Terry Williams, ISBG's Chief Executive Officer. "In addition, we anticipate it will build instant brand loyalty."
Related Quotes
ISBG
0.0005
-8.33%
International Spirit & Beverag …? Watchlist
0.0005-0.00(8.33%)
OTC MarketsFri, Mar 18, 2016 3:54 PM EDT
INTERNATIONAL SPIRIT & BEVERAGE GROUP, INC. Financials EDGAR Online Financials 2 mths ago
More
ISBG believes the diverse exposure across Giants platforms will further pave the way to an extremely bright near-term future. While ISBG management couldn't be more excited about its relationship with the New York Giants, this is just the first of many major sponsorship deals in the pipeline.
About New York Giants:
A cornerstone franchise of the National Football League, the New York Football Giants began play in 1925. With eight championships, including a victory over the New England Patriots in Super Bowl XLIV, their second in five seasons, the Giants are the only franchise in the NFL with a Super Bowl victory in each of the last four decades. Headquartered at the Quest Diagnostics Training Center in East Rutherford, N.J., the Giants entered their 91st season of play this fall. www.giants.com
About (ISBG) International Spirit and Beverage Group:
International Spirit and Beverage Group is an authorized importer, licensor, and marketer of alcoholic beverages. The ISBG initial portfolio consists of Besado Tequila, Dziaq Liqueur, and Cavoda Vodka. To learn more about ISBG, please visit www.isbg.global or @drinkisbg on Twitter.
About ISBG Mission:
Our mission at ISBG is to cultivate an atmosphere of excellence and spiritual values. We exist to create experiences where passion and purpose come together. We are certainly in the pursuit of becoming a leader in the industry, while at the same time using business to inspire.
We value our relationship with the community we serve, and the opportunity to encourage and mentor children across the globe.
We will continue to build the best products; while we help our customers celebrate life.
Notice Regarding Forward Looking Statements:
This news release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. When used in this release, words such as "estimate", "expect", "anticipate", "projected", "planned", "forecasted", and similar expressions are intended to identify forward-looking statements, which are, by their very nature, no guarantees of ISBG's future operational or financial performance, and are subject to risks and uncertainties. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Due to the risks and uncertainties, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-new-york-football-giants-team-up-with-isbg-300167069.html
$PMCB PharmaCyte’s Novel Diabetes Treatment Approach Could Prove Superior to Other Methods Under Development
Forecasts for the number of people that will be diagnosed with diabetes in the coming years are staggering. While many treatments exist to treat some of the effects of diabetes on patients afflicted with the disease, a “holy grail” to truly treat the disease has yet to be developed. Clearly, an out of the box approach is required. If future test results affirm the data derived from recent studies, the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® diabetes treatment platform could emerge as the treatment of choice for this disease.
Dozens of studies and trials to treat Type 1 and Type 2 diabetes are ongoing, given that the size of the global diabetes market for therapeutic devices and drugs is expected to reach US $114.3 billion by 2018, according to a report by Transparency Market Research. However, since results have been mixed for even the largest and most successful companies, industry participants are now exploring new ideas and new approaches that have demonstrated efficacy in early studies, which could serve as an indirect or direct benefit to PharmaCyte.
For example, one of the top two players in diabetes treatment, Novo Nordisk (NYSE – NVO), announced that it is collaborating with IBM (NYSE – IBM) to combine IBM’s cognitive computing capabilities with diabetes research by collecting and analyzing real-time data from patients using Novo Nordisk treatments and devices. The hope is that this venture leads to improved solutions for diabetes management. Novo Nordisk also submitted a new type of fast-acting mealtime insulin to the FDA for approval, a departure from its primary offerings. Meanwhile, Novo Nordisk competitor Eli Lilly (NYSE – LLY), which has had six diabetes treatments approved since 2014 halted development of a promising diabetes treatment under development. If a company with 6 approved drugs in a treatment category is still working on the problem, and another leader is moving outside of its comfort zone in an effort to develop the most effective therapy available, it is an indication that the time is now for PharmaCyte.
The Company has the exclusive worldwide rights to use Melligen cells to treat diabetes. Melligen cells are genetically engineered from human liver cells and have been shown to secrete insulin in response to the concentrations of glucose (blood sugar) in their environment. A recent article published in scientific journal Molecular Therapy noted that when Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal.
This observation illustrates that Melligen cells can reverse the diabetic condition. PharmaCyte plans to encapsulate a human cell line that has been genetically modified to produce, store and release insulin in response to blood glucose levels in their surroundings. Therefore, the Melligen cell line, when combined with Cell-in-a-Box® encapsulation, could ultimately become a treatment that has clear advantages over current therapies used for Type 1 diabetes and Type 2 insulin-dependent diabetes and could potentially replace them. As a result, we look for these shares to move toward the $0.20 level in early 2016.
$PMCB PharmaCyte’s Novel Diabetes Treatment Approach Could Prove Superior to Other Methods Under Development
Forecasts for the number of people that will be diagnosed with diabetes in the coming years are staggering. While many treatments exist to treat some of the effects of diabetes on patients afflicted with the disease, a “holy grail” to truly treat the disease has yet to be developed. Clearly, an out of the box approach is required. If future test results affirm the data derived from recent studies, the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® diabetes treatment platform could emerge as the treatment of choice for this disease.
Dozens of studies and trials to treat Type 1 and Type 2 diabetes are ongoing, given that the size of the global diabetes market for therapeutic devices and drugs is expected to reach US $114.3 billion by 2018, according to a report by Transparency Market Research. However, since results have been mixed for even the largest and most successful companies, industry participants are now exploring new ideas and new approaches that have demonstrated efficacy in early studies, which could serve as an indirect or direct benefit to PharmaCyte.
For example, one of the top two players in diabetes treatment, Novo Nordisk (NYSE – NVO), announced that it is collaborating with IBM (NYSE – IBM) to combine IBM’s cognitive computing capabilities with diabetes research by collecting and analyzing real-time data from patients using Novo Nordisk treatments and devices. The hope is that this venture leads to improved solutions for diabetes management. Novo Nordisk also submitted a new type of fast-acting mealtime insulin to the FDA for approval, a departure from its primary offerings. Meanwhile, Novo Nordisk competitor Eli Lilly (NYSE – LLY), which has had six diabetes treatments approved since 2014 halted development of a promising diabetes treatment under development. If a company with 6 approved drugs in a treatment category is still working on the problem, and another leader is moving outside of its comfort zone in an effort to develop the most effective therapy available, it is an indication that the time is now for PharmaCyte.
The Company has the exclusive worldwide rights to use Melligen cells to treat diabetes. Melligen cells are genetically engineered from human liver cells and have been shown to secrete insulin in response to the concentrations of glucose (blood sugar) in their environment. A recent article published in scientific journal Molecular Therapy noted that when Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal.
This observation illustrates that Melligen cells can reverse the diabetic condition. PharmaCyte plans to encapsulate a human cell line that has been genetically modified to produce, store and release insulin in response to blood glucose levels in their surroundings. Therefore, the Melligen cell line, when combined with Cell-in-a-Box® encapsulation, could ultimately become a treatment that has clear advantages over current therapies used for Type 1 diabetes and Type 2 insulin-dependent diabetes and could potentially replace them. As a result, we look for these shares to move toward the $0.20 level in early 2016.
Yes....the entire Model X is all about the Falcon Wings. They looks pretty sleek and cool my Friend.
$PMCB PharmaCyte’s Innovative Platform Now Set to Target Multiple Deadly Cancers
Recent company news is a strong reminder that the potential value of the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® platform technology is in the billions since it has proven to be effective in treating varying forms of cancer in preclinical and clinical tests. In fact, the Company’s platform could be potentially used to treat over 265,000 new patients suffering from varying forms of abdominal cancer and the 232,000 new patients diagnosed with breast cancer each year.
Abdominal Cancers
According to the American Cancer Society, hundreds of thousands of new cases of abdominal cancers in the U.S. are diagnosed annually. These include but are not limited to:
Colorectal: 132,000
Liver: 62,000
Pancreatic: 49,000
Ovarian: 22,000
To date, PharmaCyte’s live cell encapsulation technology, known as “Cell-in-a-Box®”, plus low-dose ifosfamide has successfully completed mid-stage clinical trials in pancreatic cancer. PharmaCyte could be just months away from a pre-IND meeting with the FDA to discuss plans for the next stage of clinical trials. Leveraging the solid results from completed trials and studies with PharmaCyte’s platform technology, PharmaCyte initiated preclinical studies designed to determine the effectiveness of Cell-in-a-Box® plus ifosfamide therapy in delaying the accumulation of malignant ascites fluid in the abdomen of mice with abdominal tumors.
PharmaCyte’s initial series of preclinical studies were conducted with mice that had been inoculated with a human ovarian cancer. The data is being used as a foundation for future studies on other tumor types. For example, the results from PharmaCyte’s initial series of studies are now being used in connection with new colon cancer studies that may prove to be effective in developing a treatment that delays the production of malignant ascites fluid in cancer patients. In fact, the new study is based upon the results of previous work using this same model system that was performed by Dr. Matthias Löhr, the Chairman of PharmaCyte’s Scientific Advisory Board, and his colleagues at the University of Heidelberg, Germany. The results of the previous study were reported in the scientific publication Cancer Gene Therapy in 2006.
PharmaCyte hopes to replicate the earlier study results which demonstrated that a combination of the Cell-in-a-Box® capsules and ifosfamide is effective in treating the spread of colon cancer that was caused by malignant ascites fluid. This fluid is produced by abdominal cancers and is largely responsible for the spread of cancer cells from the original tumor to other sites in the peritoneal cavity. According to management, if successful, PharmaCyte will have developed a treatment that will help combat the spread of abdominal tumors and reduce the suffering of cancer patients from the production of ascites fluid within the abdominal cavity.
Breast Cancer
PharmaCyte’s platform technology plus low-dose ifosfamide has also achieved enviable success in efforts to develop a treatment for one of the most high profile cancers that are attributed to well over 200,000 new cases annually - breast cancer. In fact, the medical journal PLOS One published a study in which a Phase I/II clinical trials was conducted in dogs with spontaneously occurring mammary tumors which produced stellar results. (http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0102061). It should be noted that this animal model is closely related to the development of breast cancer in humans. As one might expect, the study results were remarkably similar to the earlier human Phase I/II pancreatic cancer trial using PharmaCyte’s platform technology.
In the trial, which included 16 female dogs, cyclophosphamide was chosen as the pro-drug instead of the pro-drug the ifosfamide used in the earlier pancreatic trials. That is because cyclophosphamide is a standard chemotherapeutic agent used in combination with others for the treatment of mammary cancer in dogs as well as breast cancer in humans. Since both cyclophosphamide and ifosfamide are “sister” pro-drugs and are converted to their cancer-killing forms in the same way, the same type of encapsulated live cells were used in both the pancreatic and mammary cancer studies. As in the human pancreatic cancer trials, the capsules were well tolerated in the mammary cancer trials, with no major safety issues. Importantly, far greater tumor shrinkage was observed in those dogs treated with encapsulated cells as well as the pro-drug versus those receiving cyclophosphamide alone.
Interestingly, prior to receiving approval for Abraxane as a treatment for pancreatic cancer, Celgene (NASDAQ – CELG) was awarded FDA approval to use the treatment for breast cancer. Since breast cancer is easier to treat and has a much higher survival rate than pancreatic cancer, it is conceivable that if PharmaCyte is successful in garnering FDA approval for pancreatic cancer, a breast cancer treatment approval could be a slam dunk.
The bottom line? If the favorable data from previous trials and studies for multiple cancer indications are any indication of potential future results, PharmaCyte’s novel approach could emerge as one of the most effective and diverse cancer treatment platforms in the market for solid tumors of all kinds and could be worth billions of dollars.
$PMCB Scientists have created insulin-producing cells that could replace injections
Australian scientists from the University of Technology, Sydney (UTS), have created a line of insulin-producing cells that could eliminate the need for Type 1 diabetics to inject themselves with insulin.
The development on its own is pretty impressive, but the cells, which are derived from liver cells, are now on their way to being incorporated to a world-first bio-artificial pancreas after being licensed by US biotechnology company PharmaCyte Biotech last October.
PharmaCyte Biotech has already acquired something called the Cell-in-a-Box® system, which is basically a tiny cellulose-based ‘capsule’ that can house artificial cells and integrate them into a human body. This platform can be used to develop treatments for any disease where cells aren’t releasing the molecules they’re supposed to, but after acquiring the license to the insulin-producing cells, it’s clear that PharmaCyte Biotech has set their sites on targeting Type 1 diabetes.
Type 1 diabetes or juvenile-onset diabetes is an autoimmune disease that occurs when a person’s immune system attacks their pancreas’s islet cells and prevents it from properly regulating the body’s blood glucose levels by releasing insulin.
The new cell line, called “Melligen” cells, is derived from human liver cells, which have been genetically modified to take over the role of the pancreas’s insulin-producing islet cells.
“When a foetus develops, the liver and the pancreas form from the same endodermal origin,” explained Ann Simpson from UTS:Science, who has been developing the cells over the past 20 years, in a press release. Which means that they should have the potential to do the same things as one another.
Early lab trials have shown that the genetically modified Melligen cells are able to release insulin in direct response to the amount of glucose in their surroundings – something that could help type 1 diabetics to live without daily injections and regulate their blood sugar levels naturally.
“My team and I are excited by the prospect of working with PharmaCyte Biotech to eliminate daily injections for insulin-dependent diabetic patients,” said Simpson in the release.
The next step for the company is for PharmaCyte Biotech to embed clusters of the Melligen cells into the Cell-in-a-Box® capsule, which is around the size of a pin head.
These artificial pancreases will then be transplanted into animals to test whether they can effectively integrate into the body and regulate insulin levels. After that, they can begin testing the technology in humans.
Several other groups are now working on artificial pancreases that use sensors under the skin, or even temporary tattoos to monitor blood glucose levels. But these systems all require a pump to control the amount of insulin required in response to these levels, rather than biologically sensitive cells.
It’s pretty exciting to see all the ground-breaking work on diabetes and insulin-producing cells finally be commercialized into a product that could directly change people’s lives.
—
Learn more here http://austrianova.com/healthcare/
$PMCB Scientists have created insulin-producing cells that could replace injections
Australian scientists from the University of Technology, Sydney (UTS), have created a line of insulin-producing cells that could eliminate the need for Type 1 diabetics to inject themselves with insulin.
The development on its own is pretty impressive, but the cells, which are derived from liver cells, are now on their way to being incorporated to a world-first bio-artificial pancreas after being licensed by US biotechnology company PharmaCyte Biotech last October.
PharmaCyte Biotech has already acquired something called the Cell-in-a-Box® system, which is basically a tiny cellulose-based ‘capsule’ that can house artificial cells and integrate them into a human body. This platform can be used to develop treatments for any disease where cells aren’t releasing the molecules they’re supposed to, but after acquiring the license to the insulin-producing cells, it’s clear that PharmaCyte Biotech has set their sites on targeting Type 1 diabetes.
Type 1 diabetes or juvenile-onset diabetes is an autoimmune disease that occurs when a person’s immune system attacks their pancreas’s islet cells and prevents it from properly regulating the body’s blood glucose levels by releasing insulin.
The new cell line, called “Melligen” cells, is derived from human liver cells, which have been genetically modified to take over the role of the pancreas’s insulin-producing islet cells.
“When a foetus develops, the liver and the pancreas form from the same endodermal origin,” explained Ann Simpson from UTS:Science, who has been developing the cells over the past 20 years, in a press release. Which means that they should have the potential to do the same things as one another.
Early lab trials have shown that the genetically modified Melligen cells are able to release insulin in direct response to the amount of glucose in their surroundings – something that could help type 1 diabetics to live without daily injections and regulate their blood sugar levels naturally.
“My team and I are excited by the prospect of working with PharmaCyte Biotech to eliminate daily injections for insulin-dependent diabetic patients,” said Simpson in the release.
The next step for the company is for PharmaCyte Biotech to embed clusters of the Melligen cells into the Cell-in-a-Box® capsule, which is around the size of a pin head.
These artificial pancreases will then be transplanted into animals to test whether they can effectively integrate into the body and regulate insulin levels. After that, they can begin testing the technology in humans.
Several other groups are now working on artificial pancreases that use sensors under the skin, or even temporary tattoos to monitor blood glucose levels. But these systems all require a pump to control the amount of insulin required in response to these levels, rather than biologically sensitive cells.
It’s pretty exciting to see all the ground-breaking work on diabetes and insulin-producing cells finally be commercialized into a product that could directly change people’s lives.
—
Learn more here http://austrianova.com/healthcare/
$GRNH ~ GreenGro Technologies, Inc. due diligence report
$GRNH recent news/filings
## source: finance.yahoo.com
Tue, 05 Jan 2016 13:00:00 GMT ~ BP Gardens Addressing Agricultural Challenges in Nicaragua Amid Country's Blue Revolution
[Marketwired] - GreenGro Technologies a world-class provider of eco-friendly green technologies announced today that its subsidiary, BP Gardens, a controlled environment agriculture company specializing in the use of ...
read full: http://finance.yahoo.com/news/bp-gardens-addressing-agricultural-challenges-130000373.html
*********************************************************
Tue, 05 Jan 2016 13:00:00 GMT ~ Gala Global Reveals the Creation of a Specialized Medical Marijuana Advisory Board to Consult on Marijuana Business in California
[Accesswire] - Board to Consult Company and Subsidiaries on Assembly Bills 266, 243 and Senate Bill 643 LOS ANGELES, CA / ACCESSWIRE / January 5, 2016 / Gala Global, Inc. (PINKSHEETS: GLAG), a startup supplier of new ...
read full: http://finance.yahoo.com/news/gala-global-reveals-creation-specialized-130000161.html
*********************************************************
Tue, 08 Dec 2015 18:18:32 GMT ~ GREENGRO TECHNOLOGIES, INC. Financials
read full: http://finance.yahoo.com/q/is?s=grnh
*********************************************************
Tue, 08 Dec 2015 12:00:00 GMT ~ Greengro Technologies System Sales Surge as California Medical Marijuana Law AB266 Approaches
[Marketwired] - Greengro Technologies announced today several new orders for its advanced greenhouse systems and stated that in store sales for November were 100% higher than October and December is setting new records....
read full: http://finance.yahoo.com/news/greengro-technologies-system-sales-surge-120000572.html
*********************************************************
Tue, 03 Nov 2015 13:00:00 GMT ~ Greengro Technologies Signs Sweet Leaf Hydroponics as Exclusive Northern California Reseller
[Marketwired] - Greengro Technologies announced today it has appointed Sweet Leaf Hydroponics as its exclusive value added dealer for Northern California. Sweet Leaf is the central valley's largest full service reseller ...
read full: http://finance.yahoo.com/news/greengro-technologies-signs-sweet-leaf-130000045.html
*********************************************************
$GRNH charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$GRNH company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/GRNH/company-info
Ticker: $GRNH
OTC Market Place: OTC Pink Current
CIK code: 0000850083
Company name: GreenGro Technologies, Inc.
Company website: http://www.greengrotech.com
Incorporated In: NV, USA
Business Description: GreenGro Technologies, Inc. is a publicly traded pink sheet corporation that providesmanufacturing and sales of green, eco-friendly, sustainable vertical cultivation systems, and facilities design. GreenGro's products and services are targeted at consumers, industrial farming operations. GreenGro's products and services are designed to provide all of these customers' solutions to achieve maximum efficiency, whether that be a balcony garden or industrial cultivator.GreenGro's Vertical Cultivation and Gardening Systems are based upon patent pending designs and manufacturing facilities recently acquired by purchasing the company Vertical Hydrogarden. This system is a revolutionary technology system that reduces the physical footprint of cultivating, while reducing energy costs and improving crop yields. Operating Divisions:GRNH provides design and consulting services to all agricultural divisions including legalized Cannabis operations. It provides the expert knowledge in advanced designs and systems to maximize production for every crop cycle. Vertical Hydrogarden, Inc. (VHI) a leading supplier of green agriculture products including hydroponics, advanced nutrients, and vertical cultivation technology systems design and sales. The new retail Hydroponics Superstore operations features new technology application for greenhouse systems.BP Gardens specializes in the use of leading-edge technologies and state-of-the-artproduction methods. BP Gardens uses methods to protects crops from detrimentalenvironmental elements while generating superior, high-quality, locally grown, market ready leafy green produce year-round in any climate.Less >>
$GRNH share structure
## source: otcmarkets.com
Market Value: $9,562,870 a/o Jan 08, 2016
Shares Outstanding: 233,240,723 a/o Sep 30, 2015
Float: 160,400,788 a/o Jun 30, 2015
Authorized Shares: 500,000,000 a/o Sep 30, 2015
Par Value: 0.01
$GRNH extra dd links
Company name: GreenGro Technologies, Inc.
Company website: http://www.greengrotech.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=GRNH+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=GRNH+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=GRNH+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/GRNH/news - http://finance.yahoo.com/q/h?s=GRNH+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/GRNH/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/GRNH/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=GRNH+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/GRNH
DTCC (dtcc.com): http://search2.dtcc.com/?q=GreenGro+Technologies%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=GreenGro+Technologies%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=GreenGro+Technologies%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.greengrotech.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.greengrotech.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.greengrotech.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/GRNH
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000850083&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/GRNH/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/GRNH/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=GRNH&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=GRNH
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/GRNH/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=GRNH+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=GRNH+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=GRNH
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=GRNH
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=GRNH+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/GRNH/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=GRNH+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/GRNH.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=GRNH
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/GRNH/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/GRNH
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/GRNH
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/GRNH:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=GRNH
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=GRNH
$GRNH ~ GreenGro Technologies, Inc. due diligence report
$GRNH recent news/filings
## source: finance.yahoo.com
Tue, 05 Jan 2016 13:00:00 GMT ~ BP Gardens Addressing Agricultural Challenges in Nicaragua Amid Country's Blue Revolution
[Marketwired] - GreenGro Technologies a world-class provider of eco-friendly green technologies announced today that its subsidiary, BP Gardens, a controlled environment agriculture company specializing in the use of ...
read full: http://finance.yahoo.com/news/bp-gardens-addressing-agricultural-challenges-130000373.html
*********************************************************
Tue, 05 Jan 2016 13:00:00 GMT ~ Gala Global Reveals the Creation of a Specialized Medical Marijuana Advisory Board to Consult on Marijuana Business in California
[Accesswire] - Board to Consult Company and Subsidiaries on Assembly Bills 266, 243 and Senate Bill 643 LOS ANGELES, CA / ACCESSWIRE / January 5, 2016 / Gala Global, Inc. (PINKSHEETS: GLAG), a startup supplier of new ...
read full: http://finance.yahoo.com/news/gala-global-reveals-creation-specialized-130000161.html
*********************************************************
Tue, 08 Dec 2015 18:18:32 GMT ~ GREENGRO TECHNOLOGIES, INC. Financials
read full: http://finance.yahoo.com/q/is?s=grnh
*********************************************************
Tue, 08 Dec 2015 12:00:00 GMT ~ Greengro Technologies System Sales Surge as California Medical Marijuana Law AB266 Approaches
[Marketwired] - Greengro Technologies announced today several new orders for its advanced greenhouse systems and stated that in store sales for November were 100% higher than October and December is setting new records....
read full: http://finance.yahoo.com/news/greengro-technologies-system-sales-surge-120000572.html
*********************************************************
Tue, 03 Nov 2015 13:00:00 GMT ~ Greengro Technologies Signs Sweet Leaf Hydroponics as Exclusive Northern California Reseller
[Marketwired] - Greengro Technologies announced today it has appointed Sweet Leaf Hydroponics as its exclusive value added dealer for Northern California. Sweet Leaf is the central valley's largest full service reseller ...
read full: http://finance.yahoo.com/news/greengro-technologies-signs-sweet-leaf-130000045.html
*********************************************************
$GRNH charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$GRNH company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/GRNH/company-info
Ticker: $GRNH
OTC Market Place: OTC Pink Current
CIK code: 0000850083
Company name: GreenGro Technologies, Inc.
Company website: http://www.greengrotech.com
Incorporated In: NV, USA
Business Description: GreenGro Technologies, Inc. is a publicly traded pink sheet corporation that providesmanufacturing and sales of green, eco-friendly, sustainable vertical cultivation systems, and facilities design. GreenGro's products and services are targeted at consumers, industrial farming operations. GreenGro's products and services are designed to provide all of these customers' solutions to achieve maximum efficiency, whether that be a balcony garden or industrial cultivator.GreenGro's Vertical Cultivation and Gardening Systems are based upon patent pending designs and manufacturing facilities recently acquired by purchasing the company Vertical Hydrogarden. This system is a revolutionary technology system that reduces the physical footprint of cultivating, while reducing energy costs and improving crop yields. Operating Divisions:GRNH provides design and consulting services to all agricultural divisions including legalized Cannabis operations. It provides the expert knowledge in advanced designs and systems to maximize production for every crop cycle. Vertical Hydrogarden, Inc. (VHI) a leading supplier of green agriculture products including hydroponics, advanced nutrients, and vertical cultivation technology systems design and sales. The new retail Hydroponics Superstore operations features new technology application for greenhouse systems.BP Gardens specializes in the use of leading-edge technologies and state-of-the-artproduction methods. BP Gardens uses methods to protects crops from detrimentalenvironmental elements while generating superior, high-quality, locally grown, market ready leafy green produce year-round in any climate.Less >>
$GRNH share structure
## source: otcmarkets.com
Market Value: $9,562,870 a/o Jan 08, 2016
Shares Outstanding: 233,240,723 a/o Sep 30, 2015
Float: 160,400,788 a/o Jun 30, 2015
Authorized Shares: 500,000,000 a/o Sep 30, 2015
Par Value: 0.01
$GRNH extra dd links
Company name: GreenGro Technologies, Inc.
Company website: http://www.greengrotech.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=GRNH+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=GRNH+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=GRNH+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/GRNH/news - http://finance.yahoo.com/q/h?s=GRNH+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/GRNH/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/GRNH/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=GRNH+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/GRNH
DTCC (dtcc.com): http://search2.dtcc.com/?q=GreenGro+Technologies%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=GreenGro+Technologies%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=GreenGro+Technologies%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.greengrotech.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.greengrotech.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.greengrotech.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/GRNH
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000850083&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/GRNH/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/GRNH/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=GRNH&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=GRNH
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/GRNH/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=GRNH+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=GRNH+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=GRNH
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=GRNH
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=GRNH+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/GRNH/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=GRNH+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/GRNH.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=GRNH
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/GRNH/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/GRNH/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/GRNH
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/GRNH
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/GRNH:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=GRNH
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=GRNH
Thanks again my Friend
$USMJ I am holding this Baby
Agreed
Go $MMHC
Nice
Go $IENG